In
most gene therapy studies, a «normal» gene is inserted into the genome to replace an «abnormal,» disease - causing gene.
Not exact matches
«I've been doing this for more than 40 years and this is one of the
most exciting developments we've seen,» says Jerry Mendell, MD, lead author of the
study and director of the Center for
Gene Therapy at Nationwide Children's.
UPenn
gene therapy researcher Jean Bennett, who heads that
study (which is separate from Jacobson's) and reported the
most dramatic improvements in patients» vision, says those gains seem stable for as long as 7.5 years.
Recently published in the journal Oncotarget, this new
study is the
most recent in a long line of
studies led by Paul B. Fisher, M.Ph., Ph.D., investigating the use of viral
gene therapy to treat a variety of cancers.
Most recently, she has led the planning and execution of a program for a new
gene therapy product candidate, from ideation through proof - of - concept
study, and mapping out the development plan.
Led by Florian Eichler, MD, from Harvard Medical School and Massachusetts General Hospital, the
study tested the first successful
gene therapy treatment for cerebral adrenoleukodystrophy (ALD), a fatal degenerative brain disease that
most severely affects boys.
«The ability to direct a
gene to a specific cell type and prevent expression in other cell types is a powerful new tool that allows us to bypass one of the
most troubling safety concerns facing
gene therapy,» said Michael Parmacek, MD, assistant professor of medicine at the University of Chicago and director of the
study.
«Our goal has been to expand the
study of
gene therapy beyond Type 1 infants to address the urgent medical needs of children with SMA Type 2, and we look forward to understanding the potential clinical impact of AVXS - 101 in these patients who, left untreated, will never walk on their own and
most will never stand without assistance.»